Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 5 to 12 years old~* pathogenic deletions or mutations of the SHANK3 gene~* stable medication regimens for at least three months prior to enrollment~Exclusion Criteria:~* closed epiphyses~* active or suspected neoplasia~* intracranial hypertension~* hepatic insufficiency~* renal insufficiency~* cardiomegaly / valvulopathy~* history of allergy to IGF-1 or any component of the formulation (mecasermin)~* history of extreme prematurity (\<1000 grams) with associated early neo-natal complications, e.g. intra-cerebral hemorrhage, prolonged hypoxia, prolonged hypoglycemia~* patients with comorbid conditions deemed too medically compromised to tolerate the risk of experimental treatment with IGF-1

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Insulin-Like Growth Factor-1 (IGF-1) (Type: EXPERIMENTAL): Injection
- Normal saline (Type: PLACEBO_COMPARATOR): Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).